Chinese Hepatolgy ›› 2024, Vol. 29 ›› Issue (8): 896-899.
• Frontier, Exploration and Controversy • Previous Articles Next Articles
Received:2024-07-05
Online:2024-08-31
Published:2024-09-30
| [1] | Sneller L, Lin C, Price A, et al. RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects[J]. Microorganisms, 2024, 12(3):599. |
| [2] | Fernandes DA Silva C, Keeshan A, COOPER C. Hepatitis B virus genotypes influence clinical outcomes:A review[J]. Can Liver J, 2023, 6(3):347-352. |
| [3] | Foko S. Dynamical analysis of a general delayed HBV infection model with capsids and adaptive immune response in presence of exposed infected hepatocytes[J]. J Math Biol, 2024, 88(6):75. |
| [4] | Hou JL, Zhao W, Lee C, et al. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries[J]. Clin Gastroenterol Hepatol, 2020, 18(2):457-467,e421. |
| [5] | Alshuwaykh O, Daugherty T, Cheung A, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy[J]. Hepatol Commun, 2022, 6(11):3052-3061. |
| [6] | Yim HJ, Kang SH, Jung YK, et al. Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy[J]. Cancers (Basel), 2024, 16(5):887. |
| [7] | Zhang Q, Peng H, Liu X, et al. Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease[J]. J Clin Transl Hepatol, 2021, 9(6):850-859. |
| [8] | Varghese N, Majeed A, Nyalakonda S, et al. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma[J]. Cancers (Basel), 2024, 16(4):777. |
| [9] | Shin SK, Yim HJ, Kim JH, et al. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis[J]. Gut Liver, 2021, 15(3):430-439. |
| [10] | Suzuki F, Suzuki Y, Karino Y, et al. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients:a phase 4, prospective study[J]. BMC Gastroenterol, 2021, 21(1):489. |
| [11] | Ignat MD, Balta AAS, Barbu RE, et al. Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future[J]. J Clin Med, 2024, 13(7):2055. |
| [12] | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2):370-398. |
| [13] | Terrault NA, Lok ASF, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4):1560-1599. |
| [14] | Wang X, Cai D, Juan Z. SAT447 - Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide[J]. Chongqing Med Univ, Affiliated Hosp 2, Infect Dis, Chongqing, Peoples R China, 2022, Vol.77(Suppl 1):S878. |
| [15] | Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV:Stopping NUCs, adding interferon or new drug development?[J]. J Hepatol, 2022, 76(6):1249-1262. |
| [16] | Leowattana W, Leowattana T. Chronic hepatitis B:New potential therapeutic drugs target[J]. World J Virol, 2022, 11(1):57-72. |
| [17] | Hu JL, Huang AL. Dynamics of Hepatitis B Virus Covalently Closed Circular DNA:A Mini-Review[J]. Microorganisms, 2023, 11(3):600. |
| [18] | 王雷婕, 顾智强, 许梓萌,等. 核苷(酸)类药物经治慢性乙型肝炎患者低病毒血症发生的可能机制[J]. 中华肝脏病杂志, 2021, 29(12):1151-1155. |
| [19] | 杨瑞锋, 陈红松, 鲁凤民. 当今慢性乙型肝炎治疗实践对HBV核酸检测方法的新需求[J]. 中国临床新医学, 2021, 14(1):1-7. |
| [20] | 王贵强,王福生,庄辉,等. 慢性乙型肝炎防治指南(2019年版)[J]. 中国病毒病杂志, 2020, 10(1):1-25. |
| [21] | Wong GL, Wong VW, Chan HY, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years[J]. Aliment Pharmacol Ther, 2012, 35(11):1326-1335. |
| [22] | Sun Y, Wu X, Zhou J, et al. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11):2582-2591,e2586. |
| [23] | Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1):65-73. |
| [24] | Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2):335-343. |
| [25] | Kim TS, Sinn DH, Kang W, et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia[J]. J Gastroenterol Hepatol, 2019, 34(11):2028-2035. |
| [26] | Lee SB, Jeong J, Park JH, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir[J]. Clin Mol Hepatol, 2020, 26(3):364-375. |
| [27] | Park JH, Ahn SJ, Cho HJ, et al. Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B[J]. J Med Virol, 2016, 88(2):252-259. |
| [28] | Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B[J]. Liver Int, 2020, 40(7):1578-1589. |
| [29] | Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4):1058-1066. |
| [30] | Shin JW, Jung SW, Lee SB, et al. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir[J]. Am J Gastroenterol, 2018, 113(7):998-1008. |
| [31] | Yuen MF, Schiefke I, Yoon JH, et al. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection[J]. Hepatology, 2020, 72(1):19-31. |
| [32] | Nakanishi A, Okumura H, Hashita T, et al. Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2[J]. Viruses, 2022, 14(11):2468. |
| [33] | Philips CA, Ahamed R, Abduljaleel JK, et al. Critical Updates on Chronic Hepatitis B Virus Infection in 2021[J]. Cureus, 2021, 13(10):e19152. |
| [34] | Berke JM, Dehertogh P, Vergauwen K, et al. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus[J]. Antimicrob Agents Chemother, 2017, 61(8):e00560-17. |
| [35] | Klumpp K, Lam AM, Lukacs C, et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein[J]. Proc Natl Acad Sci U S A, 2015, 112(49):15196-15201. |
| [36] | Prifti GM, Moianos D, Giannakopoulou E, et al. Recent Advances in Hepatitis B Treatment[J]. Pharmaceuticals (Basel), 2021, 14(5):417. |
| [37] | Ide M, Tabata N, Yonemura Y, et al. Hepatitis B virus evades the immune system by suppressing the NF-κB signaling pathway with DENND2A[J]. Microbiol Spectr, 2024, 12(3):e0378523. |
| [38] | Soleiman-meigooni S, Yarahmadi A, Kheirkhah AH, et al. Recent advances in different interactions between toll-like receptors and hepatitis B infection: a review[J]. Front Immunol, 2024, 15:1363996. |
| [39] | Wang J, Chen R, Zhang R, et al. The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication[J]. Theranostics, 2017, 7(12):3090-3105. |
| [40] | Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B:A pilot study[J]. J Hepatol, 2019, 71(5):900-907. |
| [41] | Shin YW, Cho DH, Song GW, et al. A New ELISA to Overcome the Pitfalls in Quantification of Recombinant Human Monoclonal Anti-HBs, GC1102, by Commercial Immunoassays[J]. Biol Proced Online, 2018, 20:18. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
